Study Design~Type of study: Non-profit, multi-center, observational, prospective cohort study (with retrospective inclusion of the first cases performed)~Patient population: 100 patients~Date of beginning of enrollment: April 1st, 2023 (plus inclusion of patients treated since 2022)~Duration of the study: 12 months~All patients enrolled will undergo serial evaluations (Figure 1).~At Baseline we will collect (see eCRF):~Clinical data regarding medical history, clinical status and medications;~Biohumoral data (blood and urine chemistry);~Haemodynamic data (Right Heart Catheterization);~Echocardiographic data including Comprehensive 2D and Doppler Transtoracic Echocardiography and Transoesophageal Echocardiography;~Anatomical data (Cardiac CT).~At the time of procedure we will collect (see eCRF):~Procedural data including the occurrence of peri-procedural complications;~Haemodynamic data (Right Heart Catheterization).~At discharge we will collect (see eCRF):~Clinical data regarding clinical status and medications;~Biohumoral data (blood and urine chemistry);~Echocardiographic data including comprehensive 2D and Doppler Transtoracic Echocardiography;~Peri-procedural data including the occurrence of peri-procedural complications.~At 30-day follow-up we will collect (see eCRF):~Clinical data regarding medical history, clinical status and medications;~Biohumoral data (blood and urine chemistry);~Echocardiographic data including comprehensive 2D and Doppler Transtoracic Echocardiography;~At 6-month follow-up we will collect (see eCRF):~Clinical data regarding medical history, clinical status and medications;~Biohumoral data (blood and urine chemistry);~Echocardiographic data including comprehensive 2D and Doppler transthoracic echocardiography;~Haemodynamic data (Right Heart Catheterization), if clinically indicated.~At 1-year follow-up we will collect (see eCRF):~Clinical data regarding medical history, clinical status and medications;~Biohumoral data (blood and urine chemistry);~Echocardiographic data including Comprehensive 2D and Doppler Transtoracic Echocardiography;~Haemodynamic data (Right Heart Catheterization), if clinically indicated.
International Registry to collect patients with severe TR undergoing TricValve implantation from multiple Italian and European centers, aimed at:~Assessing the effect of TricValve implantation on cardiovascular and all-cause mortality, HF rehospitalization, renal function, functional capacity and quality of life.~Clarifying the haemodynamic effects of TricValve implantation and investigating their pathophysiological implications.